NCT00095108View on ClinicalTrials.gov

Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

43

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

January 31, 2007

Study Completion Date

January 31, 2007

Conditions

MelanomaKidney NeoplasmsMetastases

Interventions

DRUG

Recombinant Human Interleukin-21

Trial Locations (2)

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

98109

University of Washington/Seattle Cancer Care Alliance, Seattle

Sponsors

Lead Sponsor

All Listed Sponsors

lead

ZymoGenetics

INDUSTRY

NCT00095108 - Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer | Biotech Hunter | Biotech Hunter